临床上不能耐受标准化疗治疗的急性非淋巴细胞性白血病（ＡＮＬＬ）７例，作者称为特殊性ＡＮＬＬ，并应用小剂量足叶乙甙（ＬＤ－ＶＰ１６）诱导化疗。结果ＣＲ２例（２８．６％），ＰＲ１例（１４．３％），ＮＲ４例，ＬＤ－ＶＰ１６治疗期间４例ＮＲ患者白血病无进展，病情稳定（ＳＤ）。这对用标准化疗治疗创造机会具积极意义。ＬＤ－ＶＰｌ６无明显骨髓抑制及肝毒性。认为特殊性ＡＮＬＬ选用ＬＤ－ＶＰ１６过渡性治疗有效、安全、低毒。关键词 Clinically, 7 patients with acute non-lymphocytic leukemia (ANLL) who could not tolerate standard chemotherapy were referred to as specific ANLL and low-dose lysine-ethylacetate (LD-VP16) was used for induction chemotherapy. Results There were 2 cases of CR (28.6%), 1 case of PR (14.3%), 4 cases of NR, and 4 cases of NR patients had no progression of leukemia during LD-VP16 treatment. The condition was stable (SD). This has positive implications for the use of standard chemotherapy to create opportunities. LD-VPl6 showed no obvious myelosuppression and hepatotoxicity. The specificity of ANLL was considered to be effective, safe, and low toxicity using LD-VP16 transitional therapy. Key words